

Financial Results SALES WORLDWIDE¹

+5.6%

ON COMPARABLE OPERATIONAL BASIS*

\$6.8 BN

Strong Performance in CORE BUSINESS SEGMENTS SALES²

DIAGNOSTICS



\$1.3 BN

MEDICAL DEVICES



\$2.6 BN

NUTRITION



\$1.8 BN

ESTABLISHED PHARMACEUTICALS



\$1.2 BN

Breakthrough Invention in MEDICAL DEVICES



FREESTYLE[®] LIBRE

Now approved in the U.S.

This revolutionary system replaces blood glucose monitoring, eliminating the need for routine finger sticks.**



HEARTMATE 3[™] LEFT VENTRICULAR ASSIST SYSTEM

Launched in the U.S.

Helps a weak heart pump blood in advanced heart failure patients awaiting further treatment, including heart transplants.



MR-CONDITIONAL LABELING FOR ELLIPSE[™] ICD

Approved in the U.S.

One of Abbott's most widely-used implantable cardioverter defibrillators is now approved to improve access for patients suffering from abnormally fast heart rhythms who may need an MRI scan in the future.


Leadership in DIAGNOSTICS

POINT OF CARE

#1

Abbott is now the world leader in point of care testing.

GAME-CHANGING TECHNOLOGY[†]



Abbott continues to launch its new **Alinity[™]** diagnostics systems designed to increase laboratory efficiency while providing quality results.

¹Reported sales +28.8% ²Business segment sales are rounded. Please see our press release dated October 18, 2017, for full financial data.

*Comparable operational results are non-GAAP and include the prior year results for St. Jude Medical, and exclude the impact of exchange and prior and current year results for divested businesses. For full financial data and reconciliation of non-GAAP measures, please see our press release dated October 18, 2017.

** Finger sticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information.

[†]Not available for sale in the United States.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.